The Granheim COPD Study - Vitamin D and Strength Training

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effect of vitamin D supplementation on outcomes of 10 weeks progressive strength training in 100 ageing subjects (>45 years of age). Participants will be recruited into two similarly sized strata; one containing COPD patients and one containing healthy subjects of similar age. In each stratum, half the participants will receive vitamin D supplementation and half the participants will receive placebo

Detailed Description
-----------------
Physical activity is a potent way of relieving some of the adverse morbidities associated with COPD, such as muscle atrophy and reduced muscle quality. It is thus problematic that 20-30% of patients fail to elicit positive adaptations to training. This oddity has been ascribed inherent muscular properties, with potential links to comorbidities such as vitamin D and testosterone deficiency and the nature of the training program. In the present project, a double-blinded RCT will be performed to disclose the functional and biological efficacy of vitamin D supplementation (with concomitant ingestion of 1000 mg Ca2+) on the outcomes of 10 wks strength training in 100 aging individuals with or without COPD. The strength training intervention will be preceded by 3 weeks of progressive introduction to training protocols. 50 COPD patients and 50 healthy subjects will be allocated into two strata and separately randomized into two equally sized supplementation groups; (1) vitamin D3 and (2) placebo. The planned 50:50 ratio between COPD patients and healthy individuals may change, depending on the access to COPD patients. All subjects will perform lower-limb strength-training protocols in a contralateral manner: (leg 1) high-resistance (10 RM) and (leg 2) low-resistance (30 RM). Such a one-limb-at-a-time protocol ensures training that is unconfined by the cardiorespiratory limitations inherent to these patients, and allow comparison of the two training modalities in a manner unconfined by individual variation in exercise adaptability. A pilot study investigating the possible central pulmonary capacity limitation to two-legged strength training exercise in COPD patients will be performed. In this pilot study, we will compare exercise performance involving large and small muscle mass. In addition, all subjects will perform a selection of bilateral upper body exercises (10 RM), ensuring adequate hormonal responses and compliance to the study. The study is likely to revitalize guidelines for rehabilitation of COPD patients, and to provide vital information regarding the role of vitamin D in adaptations to strength training. For outcome measures specific to COPD pasients, final analyses will be performed on data from the COPD population only. For other outcome measures, final analyses will be performed on data merged from COPD patients and healthy subjects. An important rationale behind implementing healthy control subjects is to increase the statistical power of outcome measures unrelated to COPD epidemiology, which are of general relevance to physiological adaptation to strength training. In a related set of analyses, we will perform between-groups comparisons, including multivariate analyses. We will also compare the efficacy of high- and low-resistance strength training in COPD patients and healthy control subjects. The two training modalities are expected to result in similar muscular adaptations. In general, baseline vitamin D levels in blood, measured as 25(OH)D, is anticipated to be a determinant of the efficacy of the strength training intervention. In response to vitamin D3 supplementation, individuals with low baseline levels of 25(OH)D are expected to display more pronounced changes in biological active vitamin D, leading to more pronounced changes in functional and biological outcome measures in response to strength training. In contrast, supplementation may not lead to further elevation of blood 25(OH)D levels in individuals with high baseline levels, essentially meaning that vitamin D3 ingestion will be leveled out by or exceeded by the elimination of vitamin D derivatives. In these individuals, vitamin D3 ingestion will not have an additive effect on functional and biological outcome measures in response to strength training. To assess individual variation in vitamin D responses, data on functional and biological variables will be divided into quartiles based on baseline 25(OH)D-levels, whereupon comparisons will be made between low-end and high-end quartiles. Individual variation in responses to vitamin D supplementation and strength training will also be assessed using a mixed model approach.

Official Title
-----------------
The Granheim COPD Study: Effects of Vitamin D3-supplementation on the Efficacy of Strength Training in COPD Patients and Healthy Controls - a Double-blinded RCT

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamin D3
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
COPD group Inclusion Criteria: Stable COPD at GOLD stage II or III, FEV1/FVC < 0.7 and FEV1 <80% and >30% of predicted >45 years of age Exclusion Criteria: Unstable cardiovascular disease Chronic granulomatous Known active malignant disease within last 5 years Physically disabling muscloskeletal diseases Peroral use of steroids within last 2 months Serious psychiatric comorbidity Less than 4 weeks since last return t o habit ual condit ion from exacerbation Failing to understand Norwegian literary or verbally Medical record diagnosis of asthma More than one bout of strength training per week during the last 6 months leading up to the project Healthy control group Inclusion Criteria: - >45 years of age Exclusion Criteria: COPD Unstable cardiovascular disease Chronic granulomatous Known active malignant disease within last 5 years Physically disabling muscloskeletal diseases Peroral use of steroids within last 2 months Serious psychiatric comorbidity Failing to understand Norwegian literary or verbally Medical record diagnosis of asthma More than one bout of strength training per week during the last 6 months leading up to the project

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitamin D3+str.training, COPD & Healthy<br>Vitamin D3 capsules for 30 weeks: weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+ weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+ Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner: weeks 15-17, familiarization period week 18, test period weeks 19-28, intervention period weeks 29-30, test period | Dietary Supplement: Vitamin D3<br>* Vitamin D3 dissolved in olive oil, encapsuled<br>* Other names: cholecalciferol;|
| Placebo Comparator: Placebo+str.training, COPD & Healthy<br>Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group) Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner: weeks 15-17, familiarization period week 18, test period weeks 19-28, intervention period weeks 29-30, test period | Dietary Supplement: Placebo<br>* Olive oil, encapsuled<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle size | Muscle cell cross-sectional area measured in biopsies from m. vastus lateralis using immunohistochemistry | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Muscle phenotype | Muscle fiber type composition measured in biopsies from m. vastus lateralis using immunohistochemistry | Changes from before to after the strength training intervention (week 19 to week 28) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung function | Lung function measured using spirometry | Changes from before to after the strength training intervention (week 19 to week 28) | 
| One-legged cycling | Performance indicies measured during an incremental one-legged cycling test | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Hormones in blood | Levels of hormones in blood | Changes over the course of the intervention (week 0 to 28) | 
| Cytokines in blood | Levels of cytokines in blood | Changes over the course of the intervention (week 0 to 28) | 
| Steroids in skeletal muscle | Levels of steroids in m. vastus lateralis | Changes over the course of the intervention (week 0 to 28) | 
| Androgen-converting enzymes in skeletal muscle | Levels of androgen-converting enzymes in m. vastus lateralis | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Gene expression in skeletal muscle | RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Gene expression in skeletal muscle | RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome | Changes from before to after familiarization to strength training (week 15 to week 17) | 
| Protein abundances in skeletal muscle | Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Protein abundances in skeletal muscle | Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome | Changes from before to after familiarization to strength training (week 15 to week 17) | 
| Vitamin D in blood | Levels of vitamin D in blood | Changes over the course of the intervention (week 0 to 28) | 
| Step test | Performance and performance indicies measured during a 6 minutes step test | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Pasient-reported outcome measures, generic | Pasient-related outcome measures assessed using the generic survey SF-36 | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Pasient-reported outcome measures, COPD-specific | COPD-specific pasient-reported outcome assessed using COPD assessment test | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Body mass composition | Body mass composition measured using Dual-energy X-ray absorptiometry (DXA) | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Bilateral upper body maximal strength | The ability of muscles of the upper body to exert maximal force during dynamic movements | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Grip strength | Isometric hand grip strength | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Sit-to-stand test | Performance and performance indicies measured during a sit-to-stand test | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Unilateral lower body maximal muscle strength | The ability of muscles of the lower body to exert maximal force during dynamic movements | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Unilateral lower body muscle endurance | The ability of muscles of the lower body to perform repeated dynamic contractions at a specified submaximal load to exhaustion | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Bilateral upper body muscle endurance | The ability of muscles of the upper body to perform repeated dynamic contractions at a specified submaximal load to exhaustion | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Unilateral lower body isokinetic muscle strength | The ability of muscles of the lower body to exert maximal force during isokinetic movements | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Daily life activity level | Daily life activity level measured using accelerometer | Changes from before to after the intervention (week 0 to week 28) | 
| Muscle cell biological traits | Muscle cell biological traits, including numbers of myonuclei, satelitte cells and capillaries, measured in biopsies from m. vastus lateralis using immunohistochemistry | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Muscle mitochondrial quantities | Mitochondrial quantities measured in biopsies from m. vastus lateralis | Changes from before to after the strength training intervention (week 19 to week 28) | 
| Muscle mitochondrial functions | Mitochondrial functions measured in biopsies from m. vastus lateralis | Changes from before to after the strength training intervention (week 19 to week 28) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cachexia, Vitamin D, Muscle, Strength training